SRR33532762
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.210
- HEME_METABOLISM+0.150
- HYPOXIA+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
- XENOBIOTIC_METABOLISM+0.100
- KRAS_SIGNALING_DN+0.090
- P53_PATHWAY+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
- MTORC1_SIGNALING+0.060
- WNT_BETA_CATENIN_SIGNALING+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.340
- ALLOGRAFT_REJECTION-0.330
- IL6_JAK_STAT3_SIGNALING-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
- G2M_CHECKPOINT-0.310
- INFLAMMATORY_RESPONSE-0.310
- MYC_TARGETS_V1-0.310
- UV_RESPONSE_DN-0.280
- E2F_TARGETS-0.270
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900550 | — | — | 0.804 |
| 2 | AUR-AER6-TTM2-A-1-1-R-A742-41 | — | C | 0.802 |
| 3 | MNG703 | — | — | 0.791 |
| 4 | C3L-02163 | — | cohortSQ2 | 0.773 |
| 5 | TCGA-BT-A20P-01A-11R-A14Y-07 | — | — | 0.773 |
| 6 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.771 |
| 7 | TCGA-AO-A125-01A-11R-A10J-07 | — | B | 0.770 |
| 8 | SRR6079984 | — | — | 0.770 |
| 9 | MDT-AP-0343 | Med | Medulloblastoma | 0.769 |
| 10 | MDT-AP-0029 | Med | Medulloblastoma | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |